VDR rs7832552: Muscle Mass, Strength, and Genetic Traits
The rs7832552 polymorphism is a single-nucleotide variant investigated for subtle influences on lean body mass, body composition, and muscular performance. Although cataloged in connection to vitamin D receptor (VDR) pathways and neuromuscular physiology, modern genomic mapping firmly places this locus within the TRHR region on chromosome 8. Overall, published scientific evidence linking rs7832552 to differences in muscle mass remains limited, showing modest statistical effects rather than deterministic physical outcomes.
What each genotype means
Enhanced VDR transcriptional activity
This genotype encodes a shorter version of the vitamin D receptor protein that has been observed to exhibit higher transcriptional activity. Research suggests this may influence vitamin D signaling efficiency, though associations with muscle strength and health outcomes remain complex and vary across different populations.
The frequency of this genotype varies significantly by ancestry, reflecting the global distribution of the C allele.
Intermediate VDR activity profile
Carriers of this genotype possess one copy of each variant, resulting in a mix of the shorter and longer forms of the vitamin D receptor protein. Studies on this variant often show intermediate effects on receptor function compared to homozygous individuals, though the clinical significance of this variation is considered limited.
This is a common heterozygous genotype found across most major population groups.
Standard VDR protein length
This genotype encodes the longer form of the vitamin D receptor protein. While some studies have investigated its potential association with muscle strength or susceptibility to certain conditions, the evidence is mixed and often inconsistent across different ethnic groups.
This genotype is frequently observed, with its prevalence being highest in populations where the T allele is more common.
Genomic Context and Cross-Database Loci
Understanding variant rs7832552 requires distinguishing historical phenotypic annotations from modern genomic assemblies. While functional catalogs often evaluate this variant alongside neuromuscular and vitamin D pathway markers like VDR, reference assemblies in dbSNP locate rs7832552 on human chromosome 8 near the thyrotropin-releasing hormone receptor (TRHR) gene. In contrast, the classic FokI start-codon polymorphism (rs2228570) resides directly within exon 2 of the VDR gene on chromosome 12. Cross-referencing between consumer testing panels, candidate gene literature, and GWAS catalogs has occasionally grouped rs7832552 with metabolic, muscular, and hormonal regulators due to its historical inclusion in lean tissue mass association studies. The single-nucleotide change involves a substitution between cytosine (C) and thymine (T). In biochemical studies evaluating related start-codon modifications, alleles are frequently labeled as major versus minor forms, where variations can modulate downstream translational initiation or regional gene regulation. Disentangling the exact locus is critical for researchers examining physiological mechanisms.
Biological Mechanisms and Endocrine Pathways
Hormonal signaling cascades play an indispensable role in maintaining musculoskeletal health, protein synthesis, and metabolic balance. In skeletal muscle and adipose tissue, nuclear receptors such as the vitamin D receptor govern calcium handling, cellular differentiation, and gene transcription upon binding calcitriol. Similarly, neuroendocrine pathways mediated through thyrotropin-releasing hormone receptors impact thyroid hormone output, resting metabolic expenditure, and muscle tone. When regulatory variants alter transcription factor binding, alternative start sites, or mRNA turnover, they can subtly alter steady-state tissue responses to circulating endocrine signals. In experimental models, altered receptor efficiency affects how rapidly muscle fibers rebuild or adapt following mechanical strain. However, single-nucleotide polymorphisms do not operate in a vacuum. Instead, they interact with ambient hormone concentrations, nutritional intake, and systemic metabolic demands. The biological consequences of rs7832552 appear to reflect fine-tuning rather than significant disruption of receptor signaling pathways.
Current Scientific Evidence on Lean Mass and Strength
Multiple candidate gene and genome-wide association studies (GWAS) have screened rs7832552 for statistical links to lean tissue mass, muscle strength, and body composition. Initial investigative cohorts reported that carriers of the homozygous TT genotype exhibited modestly higher lean body mass compared to CC carriers, sparking enthusiasm for neuromuscular trait prediction. Subsequent replication efforts and larger meta-analyses, however, yielded mixed or population-specific associations. While some cohorts of postmenopausal women or athletic cohorts demonstrated slight advantages in fat-free mass and grip strength, other cohorts showed negligible differences after adjusting for age, overall body weight, and exercise regimens. Consequently, independent genetic databases evaluate the evidence strength for rs7832552 as limited. The consensus among genomic researchers is that skeletal muscle phenotypes are highly polygenic, shaped by thousands of minor genetic variants alongside physical conditioning, making isolated effects from rs7832552 small and context-dependent.
Ancestral Diversity and Allele Distribution
The frequency of rs7832552 alleles varies markedly across world populations according to global reference datasets like gnomAD and the 1000 Genomes Project. The minor T allele occurs at an estimated frequency of 38% among individuals of European ancestry. In East Asian populations, the T allele reaches higher frequencies near 48%, making it nearly as common as the reference allele. Conversely, in populations of African ancestry, the T allele is less frequent, observed in approximately 24% of tested individuals. Because allele background frequencies and surrounding linkage disequilibrium blocks differ across continental groups, an association observed in one ancestral group cannot be assumed to apply uniformly elsewhere. These ancestral discrepancies highlight why multi-ancestry validation is essential before any consumer-facing predictive scoring can be accurately interpreted.
Practical Implications for Health and Fitness
Discovering your rs7832552 genotype can offer an interesting window into personal genetics, but it cannot dictate your athletic ability or muscular potential. Variants associated with complex physical traits account for tiny fractions of variance in muscle volume and force production. In everyday life, progressive resistance training, adequate dietary protein, restful sleep, and sufficient micronutrient intake exert far greater influences on lean mass than any single SNP. Furthermore, rs7832552 is not a diagnostic marker for neuromuscular diseases or metabolic disorders. Individuals reviewing personal genomic reports should avoid altering medication, hormone therapies, or intensive supplementation programs without professional guidance. A certified genetic counselor, sports physiologist, or healthcare provider can help place consumer genetic data into proper, evidence-based perspective without overinterpreting single-locus results.
How common is this variant?
The minor T allele frequency is estimated at approximately 0.38 in European ancestries, 0.48 in East Asian ancestries, and 0.24 in African ancestries.
Frequently asked questions
Does having the rs7832552 TT genotype guarantee greater muscle mass?
No, carrying the TT genotype does not guarantee larger or stronger muscles. Complex physical traits like lean tissue mass are influenced by thousands of genetic markers combined with nutrition, exercise, and recovery habits. While studies noted small average differences between genotype groups, individual outcomes depend primarily on lifestyle factors.
Is rs7832552 considered a medical diagnosis for any disease?
No, rs7832552 is classified as a benign, non-pathogenic trait variant rather than a disease-causing mutation. It cannot diagnose muscle-wasting disorders, hormonal deficiencies, or skeletal conditions. Medical assessments should rely on standard clinical evaluations and laboratory tests.
Why do some scientific reports link rs7832552 to different genes?
Older literature and commercial testing arrays sometimes cataloged rs7832552 alongside muscle-related VDR pathways, while formal physical mapping in reference databases places the variant on chromosome 8 near TRHR. Differences in gene boundary definitions and historical cross-referencing account for these discrepancies.
Should I adjust my vitamin D or protein intake based on this SNP?
No dietary or supplementation adjustments are recommended based solely on rs7832552 status. Nutrient requirements are best guided by validated clinical blood tests, overall health status, and discussions with a physician or registered dietitian.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7832552?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in VDR
Variant in the promoter region (Cdx2 site) of the vitamin D receptor gene associated with altered intestinal calcium absorption and bone mineral density.
This variant in the Vitamin D receptor gene is associated with susceptibility to Type 1 Diabetes and autoimmune thyroid disease.
Promoter polymorphism (Cdx2) in the VDR gene associated with bone mineral density and vitamin D metabolism.
Common polymorphism (TaqI variant) in the vitamin D receptor affecting mRNA stability and bone mineral density.
Known as the TaqI polymorphism, this variant is located in the 3' UTR of the VDR gene and is associated with altered mRNA stability, influencing vitamin D signaling, cancer cachexia susceptibility, and gastric cancer risk.
Variant in the VDR promoter (Cdx-2 binding site) associated with bone mineral density and calcium absorption efficiency.